Financials
Financial year 2025
Worth noting
- The team shrank two years in a row.
Revenue
€ 16.3 million
▼ 70% vs 2023
Profit
Growing€ 11.4 million
▲ 17% vs 2023
Debts
Low€ 6.4 million
▼ 77% vs 2023
OMEGA PHARMA INNOVATION & DEVELOPMENT from Gent, company number BE0884084724, closed financial year 2025 with a result of € 11.4 million after tax. For that financial year OMEGA PHARMA INNOVATION & DEVELOPMENT recorded revenue of € 16.3 million and equity of € 240.2 million. Compared with financial year 2023, the result moved from € 9.7 million to € 11.4 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
What happened at OMEGA PHARMA INNOVATION & DEVELOPMENT?
What happened at OMEGA PHARMA INNOVATION & DEVELOPMENT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jonas Dhaenens stepped down as director. NBB
- Sonia Hollies stepped down as director. NBB
- Magali Verbraeken stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 11.4 million (▲ 17% vs 2023). Source: NBB ↗
- Anja van Winsberghe stepped down as director. NBB
- Jonas Dhaenens became a director. NBB
- Sonia Hollies became a director. NBB
- Magali Verbraeken became a director. NBB
In short
From € 9.9 million loss in 2021 to € 11.4 million profit in 2025.
Paid € 874,819 in corporate taxes since 2021.
Best year ever: 2025, with € 11.4 million profit.
Paid out € 8.5 million in dividends to the owners in total.
A new publication or filing at OMEGA PHARMA INNOVATION & DEVELOPMENT? We notify you, reason included.
Follow OMEGA PHARMA INNOVATION & DEVELOPMENTNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Perrigo Holding NV (100%). It owns 100% of Adriatic BST DOO itself.
Directors
According to the 2025 annual accounts
Magali Verbraeken
Director
Also active at: MEDGENIX BENELUX, OMEGA PHARMA TRADING, Perrigo Belgium +5 more
since 2023 · until 2029
Anja van Winsberghe
Director
Also active at: MEDGENIX BENELUX, OMEGA PHARMA TRADING, Perrigo Belgium +7 more
since 2021 · until 2026
Sonia Hollies
Director
Also active at: Perrigo Capital, Perrigo Europe Invest, OMEGA PHARMA INTERNATIONAL
since 2024 · until 2030
Jonas Dhaenens
Director
Also active at: OMEGA PHARMA TRADING, Perrigo Capital, Perrigo Holding +3 more
since 2026 · until 2032
Shareholders
100%
Participations
Adriatic BST DOO
100%
Establishments
Establishment units
Physical locations of this company
Gaston Crommenlaan 6 box 606
9050 Gent
Venecoweg 26
9810 Nazareth-De Pinte
Active since 9 October 2006
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
OMEGA PHARMA TRADING same network
€ 538,596 revenue · 2025
Perrigo Belgium same network
€ 44.6 million revenue · 2025
Perrigo Capital same network
€ 2.2 million revenue · 2025
Perrigo Holding same network
€ 48.4 million revenue · 2025
Perrigo Europe Invest same network
+9 more
Details
- Company number
- 0884.084.724
- VAT number
- BE 0884.084.724
- Registered office
- Gaston Crommenlaan 6 bus 606, 9050 Gent
- Names & denominations
- OMEGA PHARMA INNOVATION & DEVELOPMENT · OPID · INNOVATION & DEVELOPMENT
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 October 2006
- Peppol
- Active · Active since 8 Dec 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied